| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Douglas Yee | Q56985470 |
| P2093 | author name string | D Yee | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) | Q29619910 | ||
| Constitutive phosphorylation of the receptor for insulinlike growth factor I in cells transformed by the src oncogene | Q30450353 | ||
| A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. | Q33196244 | ||
| Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. | Q33858986 | ||
| Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. | Q34330174 | ||
| Insulin-like growth factors and neoplasia. | Q34330521 | ||
| Neoadjuvant trastuzumab induces apoptosis in primary breast cancers | Q34394358 | ||
| Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. | Q34545926 | ||
| The insulin-like growth factor system in hematopoietic cells | Q34632468 | ||
| Hormone responsive human breast cancer in long-term tissue culture: effect of insulin | Q35043073 | ||
| Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies | Q35840269 | ||
| IGF-I is a matter of heart | Q36088842 | ||
| Insulin-like growth factors in the treatment of neurological disease | Q36119565 | ||
| The insulin-like growth factor-I receptor as a target for cancer therapy | Q36219706 | ||
| Regulation of insulin-like growth factor I receptor gene expression in normal and pathological states. | Q36455474 | ||
| Involvement of insulin receptor substrate 2 in mammary tumor metastasis | Q37598825 | ||
| Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice | Q39560555 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells | Q40377146 | ||
| Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody | Q40386577 | ||
| Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor | Q40427703 | ||
| The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway | Q40521524 | ||
| Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression | Q40582971 | ||
| A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. | Q40607057 | ||
| Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth | Q40752579 | ||
| Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines | Q40769212 | ||
| Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice | Q41105926 | ||
| In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase | Q42799629 | ||
| Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors | Q42825930 | ||
| An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation | Q44564128 | ||
| Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. | Q44732856 | ||
| A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts | Q45073541 | ||
| IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. | Q46706373 | ||
| Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors | Q47860361 | ||
| Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. | Q52174749 | ||
| Parental imprinting of the mouse insulin-like growth factor II gene. | Q55052428 | ||
| IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation | Q55671011 | ||
| Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells | Q62267733 | ||
| Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens | Q69601253 | ||
| A single receptor binds both insulin-like growth factor II and mannose-6-phosphate | Q70047512 | ||
| Postnatal growth responses to insulin-like growth factor I in insulin receptor substrate-1-deficient mice | Q73222328 | ||
| Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues | Q73457065 | ||
| Role of insulin-like growth factor binding proteins in controlling IGF actions | Q77169819 | ||
| Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism | Q77402826 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| cancer | Q12078 | ||
| membrane protein | Q423042 | ||
| cell surface receptor | Q2476074 | ||
| preproinsulin | Q7240673 | ||
| neoplasm | Q1216998 | ||
| P304 | page(s) | 465-468 | |
| P577 | publication date | 2006-02-01 | |
| 2006-02-27 | |||
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Targeting insulin-like growth factor pathways | |
| P478 | volume | 94 |
| Q35989270 | A document clustering and ranking system for exploring MEDLINE citations |
| Q40014477 | Anti-insulin growth factor receptor therapy in Ewing sarcoma |
| Q38833040 | Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells |
| Q34107722 | Defining the pathway to insulin-like growth factor system targeting in cancer |
| Q40822940 | Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. |
| Q52641253 | Disruption of IGF‑1R signaling by a novel quinazoline derivative, HMJ‑30, inhibits invasiveness and reverses epithelial-mesenchymal transition in osteosarcoma U‑2 OS cells. |
| Q39051582 | Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. |
| Q35006620 | Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials |
| Q37542952 | Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions |
| Q37462347 | Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ERα-dependent in ERα-negative human breast cancer cells |
| Q40067100 | Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics |
| Q37696484 | Figitumumab (CP-751,871) for cancer therapy |
| Q28260374 | Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin |
| Q38246143 | Ganitumab for the treatment of small-cell lung cancer |
| Q36603956 | Genes involved in neuroendocrine tumor biology |
| Q33569159 | Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions |
| Q28476277 | High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507) |
| Q38770018 | IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. |
| Q41859770 | Identification of lung-cancer-related genes with the shortest path approach in a protein-protein interaction network. |
| Q50907929 | Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. |
| Q37047067 | Insulin-like growth factor: current concepts and new developments in cancer therapy |
| Q38215034 | Is it time to test biguanide metformin in the treatment of melanoma? |
| Q24654902 | Klotho and aging |
| Q51743685 | Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung |
| Q39944675 | Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer |
| Q34541960 | Lung cancer therapeutics that target signaling pathways: an update |
| Q34984314 | Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer |
| Q33733319 | Metformin: a therapeutic opportunity in breast cancer |
| Q36956237 | Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer |
| Q40132300 | Novel role for insulin as an autocrine growth factor for malignant brain tumour cells |
| Q33791812 | Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. |
| Q39458884 | Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation |
| Q40230735 | Precise mapping of an IGF-I-binding site on the IGF-1R. |
| Q34465028 | Retracted: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells |
| Q35001411 | Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins |
| Q34898454 | Target therapies in lung cancer |
| Q26826380 | Targeting insulin and insulin-like growth factor signaling in breast cancer |
| Q38075845 | The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium |
| Q35058305 | The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models |
| Q34115636 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q38983596 | The aging suppressor klotho: a potential regulator of growth hormone secretion |
| Q37352586 | The effect of metformin on apoptosis in a breast cancer presurgical trial. |
| Q40263696 | The essential role of the death domain kinase receptor-interacting protein in insulin growth factor-I-induced c-Jun N-terminal kinase activation |
| Q37307864 | The insulin-like growth factor system and its receptors: A potential novel anticancer target |
| Q56995355 | The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion |
| Q39531192 | The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. |
| Q37724259 | The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer |
| Q37807986 | The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease |
| Q39753305 | Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance |
| Q36544420 | Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? |
| Q55498881 | [Research progress on the relationship between insulin-like growth factor-I and lung cancer]. |
Search more.